Gastric Cancer

Papers
(The TQCC of Gastric Cancer is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
Correction to: Real-world safety and effectiveness of nivolumab in Japanese patients with unresectable advanced or recurrent gastric/gastroesophageal junction cancer that has progressed after chemothe805
Decorin as a key marker of desmoplastic cancer-associated fibroblasts mediating first-line immune checkpoint blockade resistance in metastatic gastric cancer89
An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study81
Predicting chemotherapy responsiveness in gastric cancer through machine learning analysis of genome, immune, and neutrophil signatures68
Helicobacter pylori and gastric cancer: a lysosomal protease perspective43
Risk prediction model for gastric cancer within 5 years in healthy Korean adults42
Clinicopathological significance of microsatellite instability and immune escape mechanism in patients with gastric solid-type poorly differentiated adenocarcinoma40
DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plu38
The putative pleiotropic functions of meprin β in gastric cancer38
Digital histopathological images of biopsy predict response to neoadjuvant chemotherapy for locally advanced gastric cancer37
Dose–response association between cigarette smoking and gastric cancer risk: a systematic review and meta-analysis37
Ubiquitous mitochondrial creatine kinase promotes the progression of gastric cancer through a JNK-MAPK/JUN/HK2 axis regulated glycolysis35
Metabolic reprogramming as a key regulator in Helicobacter pylori-infected gastric cancer35
Novel affibody molecules targeting the AXL extracellular structural domain for molecular imaging and targeted therapy of gastric cancer34
FERMT2 drives anoikis resistance and peritoneal metastasis by enhancing extracellular matrix deposition in gastric cancer32
International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape30
Comment on: Statin use in relation to long-term survival after gastrectomy for gastric adenocarcinoma: a Swedish population-based cohort study29
Type 2 diabetes in patients undergoing gastric cancer surgery: areas requiring disease-specific glycemic management29
Minimally invasive versus open completion total gastrectomy for remnant gastric cancer: a nationwide propensity score-matched analysis28
Prognostic significance of tertiary lymphoid structures in gastric neuroendocrine carcinoma with association to delta-like ligand 3 and neuroendocrine expressions27
Crosstalk between cancer-associated fibroblasts and immune cells in peritoneal metastasis: inhibition in the migration of M2 macrophages and mast cells by Tranilast27
Correction: International consensus on the management of metastatic gastric cancer: step by step in the foggy landscape26
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma26
Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study25
Outcomes after gastrectomy according to the Gastrectomy Complications Consensus Group (GCCG) in the Dutch Upper GI Cancer Audit (DUCA)25
Ramucirumab plus paclitaxel as a second-line treatment in HER2-positive gastric cancer: subgroup analysis of a nationwide, real-world study in Korea (KCSG-ST19-16)25
LncRNA expression signature identified using genome-wide transcriptomic profiling to predict lymph node metastasis in patients with stage T1 and T2 gastric cancer25
Serum TFF2 as a more reliable biomarker for gastric cancer and early gastric cancer: a cross-sectional population-based study24
Soluble PD-L1 as a diagnostic and prognostic biomarker in resectable gastric cancer patients23
FBXW7 regulates the sensitivity of imatinib in gastrointestinal stromal tumors by targeting MCL123
Antibody–drug conjugates in gastric cancer: from molecular landscape to clinical strategies23
The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry22
Volume of hepatoid component and intratumor M2 macrophages predict prognosis in patients with hepatoid adenocarcinoma of the stomach22
Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma21
Nivolumab plus chemotherapy in patients with HER2-negative, previously untreated, unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: 3-year follow-up of the ATTRACTION-4 ra21
Time-sequential prediction of postoperative complications after gastric cancer surgery using machine learning: a multicenter cohort study20
Circulating tumor DNA predicts clinical benefits of immune checkpoint blockade in HER2-negative patients with advanced gastric cancer20
Optimal treatment strategy after first-line induction therapy in advanced HER2-positive oeso-gastric adenocarcinoma—a retrospective, international, multicentric AGEO study20
Effect of single-shot intrathecal morphine versus continuous epidural analgesia on length of stay after gastrectomy for cancer: a retrospective cohort study19
Potential therapeutic targets discovery by transcriptome analysis of an in vitro human gastric signet ring carcinoma model19
A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer18
Systematic review of health-related quality of life (HRQoL) issues associated with gastric cancer: capturing cross-cultural differences18
Prognostic value of post-operative serum procalcitonin in gastric adenocarcinoma patients undergoing radical gastrectomy: propensity score matching analysis of extended cohort from a prospective bi-ce18
CAF promotes chemoresistance through NRP2 in gastric cancer18
Suppression of galectin-4 attenuates peritoneal metastasis of poorly differentiated gastric cancer cells18
Development and application of deep learning-based diagnostics for pathologic diagnosis of gastric endoscopic submucosal dissection specimens18
Effect of preoperative chemotherapy on the histopathological classification of gastric cancer18
Janus kinase inhibitor overcomes resistance to immune checkpoint inhibitor treatment in peritoneal dissemination of gastric cancer in C57BL/6 J mice17
Angiotensin receptor blocker and angiotensin-converting enzyme inhibitor use and survival in gastric cancer patients: a Finnish nationwide cohort study17
A systematic review on the effectiveness of robot-assisted minimally invasive gastrectomy17
Impact of adjuvant therapy on outcomes of cancer of the stomach and gastroesophageal junction in the real-world17
Numerous lesions of gastric adenocarcinoma of fundic-gland and fundic gland-mucosa type in a patient17
SUSD2+ cancer-associated fibroblasts in gastric cancer mediate the effect of immunosuppression and predict overall survival and the effectiveness of neoadjuvant immunotherapy16
Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet 16
Multi-omics sequencing of gastroesophageal junction adenocarcinoma reveals prognosis-relevant key factors and a novel immunogenomic classification16
Correction to: Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis16
Lipolysis-stimulated lipoprotein receptor promote lipid uptake and fatty acid oxidation in gastric cancer16
Factors associated with the efficacy of first-line nivolumab plus chemotherapy in advanced gastric cancer patients with deficient mismatch repair16
The RNA-binding protein YTHDF3 affects gastric cancer cell migration and response to paclitaxel by regulating EZRIN16
International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study16
Impact of histologically poorly cohesive phenotype as a prognostic factor in patients with pStage II/III gastric cancer undergoing adjuvant chemotherapy16
Investigating the role of inflammatory cytokines in mediating the effect of gut microbiota on gastrointestinal cancers: a mendelian randomization study16
Thromboembolic events in patients who received adjuvant chemotherapy for gastric cancer: a single-center retrospective study15
Removal of small extracellular vesicles inhibits the progression of peritoneal dissemination in gastric cancer15
Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis15
TMEM205 induces TAM/M2 polarization to promote cisplatin resistance in gastric cancer15
Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ15
Leptomeningeal carcinomatosis in gastric cancer: A Review15
Impact of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel delivery on postoperative survival in locally advanced oesophagogastric adenocarcinoma15
A retrospective 5-year survival analysis of surgically resected gastric cancer cases from the Japanese Gastric Cancer Association nationwide registry (2001–2013)14
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)14
Low positivity rate of fibroblast growth factor receptor 2b is associated with heterogeneous expression in gastric cancer14
Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials14
Predictive value of homologous recombination-related gene mutations in survival outcomes of first-line nivolumab plus chemotherapy for gastric cancer14
Ethnic-specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations14
ATF4-mediated circTDRD3 promotes gastric cancer cell proliferation and metastasis by regulating the miR-891b/ITGA2 axis and AKT signaling pathway14
Health-related quality-of-life outcomes with regorafenib in advanced gastric and esophagogastric junction cancer: results from the INTEGRATE trials14
Morbidity and quality of life of totally laparoscopic versus laparoscopy-assisted distal gastrectomy for early gastric cancer: a multi-center prospective randomized controlled trial (CKLASS01)13
Reply to the letter to the editor regarding “Appetite-preserving gastrectomy (APG) for esophagogastric junction cancer: preserving the residual stomach as an endocrine organ”13
Comparison of clinicopathological features of gastric carcinoma in autoimmune gastritis with and without Helicobacter pylori infection12
Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric 12
Reply to: Letter to editor on the article “Choice of PD-L1 immunohistochemistry assay influences clinical eligibility for gastric cancer immunotherapy”12
Tumor-infiltrating monocytic myeloid-derived suppressor cells contribute to the development of an immunosuppressive tumor microenvironment in gastric cancer12
N6-methyladenosine-modified MIB1 promotes stemness properties and peritoneal metastasis of gastric cancer cells by ubiquitinating DDX3X12
Minimum resection length to ensure a pathologically negative distal margin and a larger remnant stomach for esophagogastric junction cancer12
The clinical importance of the host anti-tumour reaction patterns in regional tumour draining lymph nodes in patients with locally advanced resectable gastric cancer: a systematic review and meta-anal12
Circulating tumor DNA predicts recurrence and survival in patients with resectable gastric and gastroesophageal junction cancer12
Biological and targeting differences between the rare KRAS A146T and canonical KRAS mutants in gastric cancer models11
Limitations of the cox proportional hazards model and alternative approaches in metachronous recurrence research11
Comment on:“Gastric equivalent of the ‘Holy Plane’ to standardize the surgical concept of stomach cancer to mesogastric excision: updating Jamieson and Dobson’s historic schema,” Gastric cancer, 2021 11
Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer11
Safety and feasibility of single-incision laparoscopic distal gastrectomy in overweight and obese gastric cancer patients: a propensity score-matched analysis11
Clinical epidemiology of the endoscopic, laparoscopic, and surgical resection of malignant gastric tumors in Japan, 2014–2021: a retrospective study using open data from a national claims database11
Development of adenovirus-based oncolytic virus to induce EBV lytic reactivation10
Elucidating molecular mechanisms and therapeutic synergy: irreversible HER2-TKI plus T-Dxd for enhanced anti-HER2 treatment of gastric cancer10
Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer10
CDKN2A somatic copy number amplification in normal tissues surrounding gastric carcinoma reduces cancer metastasis risk in droplet digital PCR analysis10
Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis10
Early endpoints of a randomized phase II trial of preoperative chemotherapy with S-1/CDDP with or without trastuzumab followed by surgery for HER2-positive resectable gastric or esophagogastric juncti10
Minimum resection length to ensure a pathologically negative distal margin and the preservation of a larger remnant stomach in proximal gastrectomy for early upper gastric cancer10
SOX combined with sintilimab versus SOX alone in the perioperative management of locally advanced gastric cancer: a propensity score–matched analysis10
A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer9
Gallbladder edema as a clue to zolbetuximab-associated protein-losing enteropathy in gastric cancer: a case report9
SPRY4 inhibits and sensitizes the primary KIT mutants in gastrointestinal stromal tumors (GISTs) to imatinib9
Cardiovascular and thromboembolic outcomes with immune checkpoint inhibitors in gastroesophageal cancer: a propensity score-matched cohort study9
Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma9
5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer9
LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway9
Impact of body composition on survival of PD-1/PD-L1-treated metastatic gastro-esophageal junction/gastric cancer9
Failure of evaluation on ABC classification for gastric cancer screening9
Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions9
Importance of duodenal stump reinforcement to prevent stump leakage after gastrectomy: a large-scale multicenter retrospective study (KSCC DELICATE study)9
0.47196698188782